IsoPlexis’ Single-Cell Proteomics Accelerates Nanoparticle Vaccine Development in Frontiers in Immunology Publication

Functional Proteomics Reveals Predictive Potential of Vaccine Potency

The field of vaccine development poses a unique set of challenges to researchers, who aim to improve protective immunity. Due to their high antigen density, ability to target specific cell types, and other desirable properties, nanoparticles are ideal for use as a vaccine delivery system. In a recent abstract for a forthcoming publication in Frontiers in Immunology, researchers Tsuji et al. described the development and testing of a nanovaccine which promoted anti-tumor response in humanized mice, using IsoPlexis’ single-cell proteomics technology to characterize and predict the vaccine’s function.

Previous studies identified that co-delivering tumor antigens and α-galactosylceramide (α-GalCer), which is an agonist for invariant Natural Killer T (iNKT) cells, can expand CD8α+ dendritic cells (DCs) to allow them to promote a strong anti-tumor response in mice and human PBMCs in vitro. In this study, researchers Tsuji et al. tested the efficacy of a nanovaccine which co-delivered a melanoma antigen and α-GalCer in a humanized mouse model, which mimics a human immune system and possesses both iNKT and CD8+ DCs, the murine equivalent of human CD141+ DCs.

IsoPlexis’ single-cell proteomics technology was used to identify highly polyfunctional subsets of CD8+ T cells, which correlated to vaccine potency in mice. The researchers found that multiple inoculations of the humanized mice with the nanovaccine led to upregulation of human iNKT cells, CD141+ dendritic cells, and polyfunctional human CD8+ T cells, which correlated to anti-tumor activity. These findings emphasize the utility of nanovaccines and the unique ability of human iNKT cells to license cross-priming DCs in vivo, facilitating the development of novel strategies in cancer vaccine development. IsoPlexis’ functional single-cell proteomics makes these discoveries possible, enabling highly multiplexed precision analytics and characterization of vaccines on the streamlined and automated IsoLight benchtop system.

Read the abstract now and stay tuned for more on the full publication.

Share This Article
Be in the Know.
Unlock Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.